Organogenesis (NASDAQ:ORGO - Get Free Report) shares gapped down prior to trading on Tuesday . The stock had previously closed at $4.49, but opened at $3.90. Organogenesis shares last traded at $4.14, with a volume of 1,138,044 shares changing hands.
Wall Street Analyst Weigh In
ORGO has been the subject of several recent research reports. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $7.00 price objective on shares of Organogenesis in a research note on Tuesday. BTIG Research reaffirmed a "buy" rating on shares of Organogenesis in a research note on Tuesday.
Read Our Latest Stock Report on Organogenesis
Organogenesis Price Performance
The company has a fifty day moving average of $3.44 and a 200 day moving average of $3.89. The firm has a market capitalization of $554.33 million, a P/E ratio of -25.71 and a beta of 1.70.
Organogenesis (NASDAQ:ORGO - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of $0.04 by ($0.17). Organogenesis had a negative net margin of 3.46% and a negative return on equity of 4.00%. The company had revenue of $86.69 million during the quarter, compared to the consensus estimate of $90.77 million. On average, sell-side analysts forecast that Organogenesis will post -0.07 EPS for the current year.
Insider Activity
In other Organogenesis news, insider Lori Freedman purchased 142,379 shares of the business's stock in a transaction on Thursday, June 5th. The shares were purchased at an average cost of $2.91 per share, for a total transaction of $414,322.89. Following the acquisition, the insider owned 837,437 shares of the company's stock, valued at approximately $2,436,941.67. This represents a 20.48% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In the last quarter, insiders purchased 252,264 shares of company stock worth $725,732. 33.00% of the stock is currently owned by corporate insiders.
Hedge Funds Weigh In On Organogenesis
Institutional investors have recently modified their holdings of the company. Wealth Enhancement Advisory Services LLC raised its position in shares of Organogenesis by 10.8% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 43,398 shares of the company's stock worth $187,000 after purchasing an additional 4,239 shares during the period. Wells Fargo & Company MN raised its position in Organogenesis by 29.6% in the 4th quarter. Wells Fargo & Company MN now owns 41,471 shares of the company's stock valued at $133,000 after buying an additional 9,464 shares during the last quarter. Dimensional Fund Advisors LP raised its position in Organogenesis by 18.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,789,265 shares of the company's stock valued at $8,925,000 after buying an additional 442,772 shares during the last quarter. Squarepoint Ops LLC raised its position in Organogenesis by 53.2% in the 4th quarter. Squarepoint Ops LLC now owns 126,791 shares of the company's stock valued at $406,000 after buying an additional 44,051 shares during the last quarter. Finally, Prudential Financial Inc. raised its position in Organogenesis by 92.9% in the 4th quarter. Prudential Financial Inc. now owns 237,720 shares of the company's stock valued at $761,000 after buying an additional 114,500 shares during the last quarter. 49.57% of the stock is owned by institutional investors and hedge funds.
Organogenesis Company Profile
(
Get Free Report)
Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.
Featured Articles
Before you consider Organogenesis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organogenesis wasn't on the list.
While Organogenesis currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
